Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies.
Pharmathen is committed to its vision to improve people’s lives through innovation and access to affordable medicines.
The company has one of the most extensive and advanced pipelines in the industry, with a focus on long acting injectables (LAI), sustained release and ophthalmic formulations. Pharmathen’s highly diversified portfolio consists of over 100 commercialized products, which are produced in its US FDA and EU-approved manufacturing facilities in Greece, serving 250 customers and accessed by patients in more than 90 countries worldwide.
Pharmathen is constantly strengthening its portfolio with innovative technologies and Long-Acting Therapeutic Technologies (LATTs) and has developed three fully certified technological platforms to achieve this. As a result, Pharmathen can provide a wide range of therapies which aim to improve treatment compliance for patients and support product Life Cycle Management (LCM) opportunities for customers.
Pharmathen maintains a strong presence in all major markets and collaborates with the most significant organizations in the global pharmaceutical market, supported by a broad partner network in more than 90 countries worldwide. The company ranks among the top 50 pharmaceutical research companies in Europe and is one of the largest private sector investors in research and development in Greece.
Pharmathen proudly employs more than 1,600 people from over 28 different nationalities, with 54% of its total workforce and 66% of its Research Operations Team being female. The companys enduring success is attributed to a passion for creativity, strong ethics, and the dedication of its people, who share a commitment to the companys vision of making a difference in people’s lives.
